Search for a command to run...
HER2-positive breast cancer is an aggressive form of breast cancer that expresses the human epidermal growth factor receptor 2 (HER2) responsible for the expression of approximately 15-20 percent of all breast cancer cases in the world. Although there are major breakthroughs in specific biologics like monoclonal antibodies and antibody-drug conjugates, there are still unmet medical needs that have been hindered by resistance, disease progression, and inaccessibility. This article assesses the accelerated approval program and the challenges related to regulatory issues in the development of oncology biologics against HER2-positive breast cancer (Lukasiewicz et al., 2021; Nolan et al., 2023; Zimmerman & Esteva, 2024; Liu et al., 2024). This work uses a Stage-Gate model augmented with business development and financial analysis to review the lifecycle of a new HER2-targeted biologic, and specifically development timelines, regulatory approach, and commercialization issues. Important points of the research are that accelerated approval pathways, despite saving time to market, create uncertainties associated with surrogate endpoint, confirmatory trials and post-marketing requirements. The overall development process will be estimated to take 8-12 years, and the clinical development will occur during major investment (National Academies Press, 2009; Sampaio et al., 2026; Kantor & Haga, 2021). The strategic recommendations would be early regulatory interaction, adaptive trial design, and collaboration with other well-established oncology companies in order to reduce risk. Consistent with established frameworks for antineoplastic biologic development and regulatory submission (Uppula et al., 2026), the research finds that although the benefits of accelerated approval pathways are significant in oncology, planning is fundamental and needs to take into account regulatory and clinical issues to achieve success in the long term (Kantor & Haga, 2021; Liu et al., 2024). Keywords: HER2-positive breast cancer, oncology biologics, accelerated approval, regulatory challenges, Stage-Gate process, monoclonal antibodies